🟢 Iovance Biotherapeutics is trading 18.93% up after lifting 2026 revenue outlook to $410–$420 million

Iovance Biotherapeutics is trading at $13.07, up +18.93%, after raising its 2026 revenue guidance to $410–$420 million.

• The new range is $55 million higher at the midpoint than the prior range; the company cited strong U.S. demand for Amtagvi and Proleukin.
• The higher outlook is the clearest company-specific catalyst identified for the September 29 move.
• Available coverage identifies no separate confirmed catalyst, while supplied market-index figures show modest mixed moves rather than a broad-market explanation.